Envarsus XR Launched for Kidney Transplant Rejection Prophylaxis

Envarsus XR Launched for Kidney Transplant Rejection Prophylaxis
Envarsus XR Launched for Kidney Transplant Rejection Prophylaxis

Veloxis announced that Envarsus XR (tacrolimus extended-release) tablets are now available for the prophylaxis of rejection in kidney transplant patients converted from immediate-release tacrolimus formulations, in combination with other immunosuppressants.

Envarsus XR is intended for once-daily dosing, providing flatter pharmacokinetics and higher bioavailability compared to twice-daily tacrolimus. 

RELATED: Envarsus XR Approved for Organ Rejection Prophylaxis

Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin inhibited. Tacrolimus inhibits the expression and/or production of several cytokines, inhibits IL-2 receptor expression and nitric oxide release, induces apoptosis and production of transforming growth factor-beta that can lead to immunosuppressive activity. The net result is the inhibition 13 of T-lymphocyte activation and proliferation as well as T-helper-cell-dependent B-cell response.

Envarsus XR was granted Orphan Drug status by the Food and Drug Administration. It is supplied as 0.75mg, 1mg, and 4mg strength tablets in 30- and 100-count bottles. 

For more information call (844) 835-6947 or visit EnvarsusXR.com.

Loading links....